Anxiety News and Research

Latest Anxiety News and Research

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

NUVIGIL improves wakefulness in patients with excessive sleepiness associated with shift work disorder

Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).

3 Nov 2009

High prevalence of nocturnal teeth grinding in patients with OSA

There is a high prevalence of nocturnal teeth grinding, or bruxism, in patients with obstructive sleep apnea (OSA), particularly in Caucasians. New research presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that nearly 1 in 4 patients with OSA suffers from nighttime teeth grinding; this seems to be especially more prevalent in men and in Caucasians compared with other ethnic groups.

3 Nov 2009

AST develops two new holiday season tip sheets for families of children with autism

Autism Spectrum Therapies (AST), an agency providing behavior therapy and other autism services throughout Southern California, has developed two new holiday season tip sheets especially for families of children with autism: Stress-Free Holidays and Top Toy Recommendations.

3 Nov 2009

A look at faculty health

On average, research shows, the United States loses the equivalent of at least one entire medical school class each year to suicide1 - as many as 400 physicians. The book Faculty Health in Academic Medicine: Scientists, Physicians, and the Pressures of Success (Humana Press/Springer), by faculty at The University of Texas M. D. Anderson Cancer Center and other national medical experts, breaks new ground in a first-of-its-kind look at faculty health.

2 Nov 2009

Deep brain stimulation can help patients with severe forms of depression

In deep brain stimulation, doctors specifically target the impaired function of certain areas of the brain with an electric brain pacemaker. For the purpose of this study, they implanted electrodes in what is known as the nucleus accumbens. That is an important part of the 'reward system' which ensures that we remember good experiences and puts us in a state of pleasant anticipation.

2 Nov 2009

American Diabetes Association launches "Stop Diabetes" campaign

Americans earn a failing grade on diabetes awareness, based on survey results released today by the American Diabetes Association. In general, Americans earned a 51% when asked a series of questions about a disease so common that it strikes every 20 seconds. The survey results revealed that many diabetes myths and misconceptions still exist, while the disease's prevalence continues to rise.

2 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

Stress-evoked changes in circuits that regulate serotonin in certain parts of the brain can precipitate a low mood and a relapse in cocaine-seeking, based on mouse studies published online this week in the Proceedings of the National Academy of Sciences.

31 Oct 2009

NARSAD to present Productive Lives Award to Randy Lewis

Randy Lewis, the SVP of supply chain and logistics for Walgreens, the nation’s largest drugstore chain, will receive the first ever Productive Lives Award from NARSAD tonight at its 22nd annual New York Awards Dinner at the Pierre Hotel.

30 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

New study reviews science behind the efficacy of biofield therapies on pain management

Biofield therapies, which claim to use subtle energy to stimulate the body's healing process, are promising complementary interventions for reducing the intensity of pain in a number of conditions, reducing anxiety for hospitalized patients and reducing agitated behaviors in dementia, over and above what standard treatments can achieve.

30 Oct 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

A step-by-step program: Cognitive behavior workbook for weight loss

Three McMaster University experts have developed a successful weight management tool in the form of a workbook which uses cognitive behaviour therapy (CBT) to achieve lasting weight loss, with the goal being health - physical health, psychological healthy and a healthy relationship with food and the body instead of an obsession with numbers.

30 Oct 2009

New herbal medicinal product for reducing mental and physical stress

Marketed under the trade name Vitango® and now available from pharmacies, the product is a special extract of a highly resilient plant called Golden Root (Rhodiola rosea) that grows in the freezing conditions of Northern Europe and Asia's mountain peaks.

29 Oct 2009

New Wake-up Light to provide pleasant wake-up experience

According to a recent survey, an overwhelming 60 percent of Americans are not satisfied with their current way of waking up. Recognizing the need for a better way to start the day, especially with the arrival of daylight saving, Philips has announced today the launch of its Wake-up Light - an innovative product that provides a more pleasant wake-up experience.

29 Oct 2009

Non-surgical alternative treatment for moderate to advanced gum disease announced

BIOLASE Technology, Inc. today announced its new Deep Pocket Therapy with New Attachment™ using the Waterlase MD™ and patented Radial Firing Perio Tips™ (RFPT) for a non-surgical alternative treatment for moderate to advanced gum disease.

29 Oct 2009

Centre for Addiction and Mental Health to say goodbye to its landmark Administration Building

The Centre for Addiction and Mental Health (CAMH) will say goodbye to its landmark Administration Building at 1001 Queen St. West in a ceremony on October 29, 2009 at 4 p.m. Demolition of the building will begin in January 2010 to make way for the next major phase of CAMH's ambitious redevelopment project, which is transforming care for Ontarians living with addiction and mental health issues.

29 Oct 2009